🇺🇸 FDA
Pipeline program

GTB-3550 TriKE® Phase I

2015LS167

Phase 2 small_molecule terminated

Quick answer

GTB-3550 TriKE® Phase I for High-risk Myelodysplastic Syndromes is a Phase 2 program (small_molecule) at GT Biopharma with 1 ClinicalTrials.gov record(s).

Program details

Company
GT Biopharma
Indication
High-risk Myelodysplastic Syndromes
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials